Dasatinib-induced pulmonary arterial hypertension – A rare late complication:
2019
Dasatinib is a dual Src/Abl tyrosine kinase inhibitor approved for frontline and second line treatment of chronic phase chronic myelogenous leukemia. Pulmonary arterial hypertension is defined by an increase in mean pulmonary arterial pressure >25 mmHg at rest. Dasatinib-induced pulmonary hypertension has been reported in less than 1% of patients on chronic dasatinib treatment for chronic myelogenous leukemia. The pulmonary arterial hypertension from dasatinib may be categorized as either group 1 (drug-induced) or group 5 based on various mechanisms that may be involved including the pathogenesis of the disease process of chronic myelogenous leukemia. There have been reports of dasatinib-induced pulmonary arterial hypertension being reversible. We report a case of pulmonary arterial hypertension in a 46-year-old female patient with chronic phase chronic myelogenous leukemia on dasatinib treatment for over 10 years. She had significant improvement in symptoms after discontinuation of dasatinib and initiati...
Keywords:
- Anesthesia
- Gastroenterology
- Proto-oncogene tyrosine-protein kinase Src
- Chronic phase chronic myelogenous leukemia
- Chronic myelogenous leukemia
- Pulmonary hypertension
- Discontinuation
- Internal medicine
- Dasatinib
- Pathogenesis
- Tyrosine-kinase inhibitor
- Medicine
- Leukemia
- second line treatment
- Cancer research
- Myeloid
- late complication
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
15
References
1
Citations
NaN
KQI